Fig. 2From: Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trialTimeline and study procedures. MIDAS: MIgraine Disability Assessment. MIDASRes: Patients with a MIDAS score reduction of at least 50% at T3. MMDRes: Patients with a MMDs reduction of at least 50% at T3. RespondersT13: Patients with a MMDs reduction from baseline of at least 50% in the last 4 weeks of observation period (after 13 erenumab administrations). T3, T6, T9, T12: follow-up visits at three, six, nine, and twelve months after first erenumab administrationBack to article page